NO314692B1 - Pseudopolymorfe former av 2-[2-[4-(bis(4-fluorfenyl)metyl]-1- piperazinyl]etoksy]eddiksyre dihydroklorid, fremgangsmåter for fremstilling avdisse, samt farmasöytisk preparat av dem - Google Patents
Pseudopolymorfe former av 2-[2-[4-(bis(4-fluorfenyl)metyl]-1- piperazinyl]etoksy]eddiksyre dihydroklorid, fremgangsmåter for fremstilling avdisse, samt farmasöytisk preparat av dem Download PDFInfo
- Publication number
- NO314692B1 NO314692B1 NO20002631A NO20002631A NO314692B1 NO 314692 B1 NO314692 B1 NO 314692B1 NO 20002631 A NO20002631 A NO 20002631A NO 20002631 A NO20002631 A NO 20002631A NO 314692 B1 NO314692 B1 NO 314692B1
- Authority
- NO
- Norway
- Prior art keywords
- bis
- methyl
- piperazinyl
- fluorophenyl
- ethoxy
- Prior art date
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims abstract description 12
- IHTYTYHXCRAMAV-UHFFFAOYSA-N acetic acid;dihydrochloride Chemical compound Cl.Cl.CC(O)=O IHTYTYHXCRAMAV-UHFFFAOYSA-N 0.000 title claims abstract 13
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 title claims abstract 13
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 20
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 title abstract 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 19
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 15
- 239000007787 solid Substances 0.000 claims description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 239000003085 diluting agent Substances 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 239000000969 carrier Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- 239000011541 reaction mixture Substances 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 238000002441 X-ray diffraction Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 229960002920 sorbitol Drugs 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 238000000634 powder X-ray diffraction Methods 0.000 description 3
- 238000001757 thermogravimetry curve Methods 0.000 description 3
- IBJKCLFDIYBWFC-UHFFFAOYSA-N 2-[2-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]ethoxy]acetamide Chemical compound C1CN(CCOCC(=O)N)CCN1C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 IBJKCLFDIYBWFC-UHFFFAOYSA-N 0.000 description 2
- BAWMMJAUVBLLEE-UHFFFAOYSA-N 2-[2-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 BAWMMJAUVBLLEE-UHFFFAOYSA-N 0.000 description 2
- HQWVDUUIOCFXPO-UHFFFAOYSA-N 2-[2-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]ethoxy]acetic acid;dihydrochloride Chemical compound Cl.Cl.C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 HQWVDUUIOCFXPO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- TTXIFFYPVGWLSE-UHFFFAOYSA-N 1-[bis(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCNCC1 TTXIFFYPVGWLSE-UHFFFAOYSA-N 0.000 description 1
- KQHRCXCLILUNBX-UHFFFAOYSA-N 2-(2-chloroethoxy)acetamide Chemical compound NC(=O)COCCCl KQHRCXCLILUNBX-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 229910016523 CuKa Inorganic materials 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000002706 dry binder Substances 0.000 description 1
- 229950003420 efletirizine Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97870193A EP0919550A1 (en) | 1997-11-26 | 1997-11-26 | Pseudopolymorphic forms of 2-2-4-bis(4-fluorophenyl)methyl-1-piperazinyl-ethoxy acetic acid dihydrochloride |
| PCT/BE1998/000184 WO1999028310A1 (en) | 1997-11-26 | 1998-11-26 | Pseudopolymorphic forms of 2-[2-[4-[bis (4-fluorophenyl) methyl]-1-piperazinyl] ethoxy]acetic acid dihydrochloride |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20002631D0 NO20002631D0 (no) | 2000-05-23 |
| NO20002631L NO20002631L (no) | 2000-05-23 |
| NO314692B1 true NO314692B1 (no) | 2003-05-05 |
Family
ID=8231072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20002631A NO314692B1 (no) | 1997-11-26 | 2000-05-23 | Pseudopolymorfe former av 2-[2-[4-(bis(4-fluorfenyl)metyl]-1- piperazinyl]etoksy]eddiksyre dihydroklorid, fremgangsmåter for fremstilling avdisse, samt farmasöytisk preparat av dem |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US6262057B1 (sl) |
| EP (2) | EP0919550A1 (sl) |
| JP (2) | JP3996348B2 (sl) |
| KR (1) | KR100557711B1 (sl) |
| CN (1) | CN100406448C (sl) |
| AR (1) | AR017676A1 (sl) |
| AT (1) | ATE203237T1 (sl) |
| AU (1) | AU735819B2 (sl) |
| BG (1) | BG64155B1 (sl) |
| BR (1) | BR9815405A (sl) |
| CA (1) | CA2310318C (sl) |
| CO (1) | CO4980892A1 (sl) |
| CZ (1) | CZ295972B6 (sl) |
| DE (1) | DE69801163T2 (sl) |
| DK (1) | DK1034171T3 (sl) |
| EG (1) | EG23776A (sl) |
| ES (1) | ES2161552T3 (sl) |
| GC (1) | GC0000094A (sl) |
| GR (1) | GR3036702T3 (sl) |
| HU (1) | HUP0100343A3 (sl) |
| ID (1) | ID24964A (sl) |
| IL (1) | IL135544A (sl) |
| MA (1) | MA26569A1 (sl) |
| MY (1) | MY119653A (sl) |
| NO (1) | NO314692B1 (sl) |
| NZ (1) | NZ504461A (sl) |
| PE (1) | PE134899A1 (sl) |
| PL (1) | PL190871B1 (sl) |
| PT (1) | PT1034171E (sl) |
| RS (1) | RS49904B (sl) |
| RU (1) | RU2182575C2 (sl) |
| SI (1) | SI20325A (sl) |
| SK (1) | SK283237B6 (sl) |
| TN (1) | TNSN98214A1 (sl) |
| TR (1) | TR200001505T2 (sl) |
| TW (1) | TWI225053B (sl) |
| UA (1) | UA54568C2 (sl) |
| WO (1) | WO1999028310A1 (sl) |
| ZA (1) | ZA9810780B (sl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002047689A2 (en) * | 2000-12-15 | 2002-06-20 | Ucb, S.A. | Use of cetirizine or efletirizine for preventing urticaria |
| CA2454564A1 (en) * | 2001-07-26 | 2003-02-06 | Ucb, S.A. | Process for the preparation of 2-(2-(4-(bis(4-fluorophenyl)methyl)-piperazin-1-yl)ethoxy)acetic acid derivatives or corresponding salt forms thereof and intermediates therefor |
| US20050181032A1 (en) * | 2002-06-25 | 2005-08-18 | Acrux Dds Pty Ltd. | Metastable pharmaceutical compositions |
| KR20050045946A (ko) | 2002-06-25 | 2005-05-17 | 애크럭스 디디에스 피티와이 리미티드 | 비정질 약학적 조성물을 이용한 경피전달속도의 제어 |
| US20070185122A1 (en) * | 2003-05-28 | 2007-08-09 | Christophe Revirron | Use of efletirizine for treating persistent allergic rhinitis |
| WO2006050909A1 (en) * | 2004-11-10 | 2006-05-18 | Ucb Farchim Sa | Novel forms of efletirizine dihydrochloride, processes for making them and pharmaceutical compositions including them |
| WO2008155777A2 (en) * | 2007-06-18 | 2008-12-24 | Cadila Healthcare Limited | Process for preparing efletrizine |
| KR101006760B1 (ko) * | 2008-07-17 | 2011-01-11 | 주식회사 진영테크 | 모터 순간 정전 복원 장치 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH505116A (it) * | 1966-11-21 | 1971-03-31 | Crc Ricerca Chim | Metodo per l'ottenimento di derivati della piperazina |
| SE409706B (sv) * | 1976-05-21 | 1979-09-03 | Astra Pharma Prod | Forfarande for framstellning av n,n-dimetyl-3-(4-bromfenyl)-3-3(3-pyridyl)-allylamin dihydroklorid monohydrat |
| FI75816C (fi) * | 1981-02-06 | 1988-08-08 | Ucb Sa | Foerfarande foer framstaellning av terapeutiskt aktiv 2-/4-(difenylmetyl)-1-piperazinyl/-aettiksyror eller dess amid. |
| UA8337A1 (uk) * | 1981-02-06 | 1996-03-29 | Бальтес Ежен | 2-[4-(дифенілметіл)-1-піперазиніл]-оцтові кислоти або їх аміди, або їх нетоксичні фармацевтично прийняті солі, що проявляють спазмолітичну і антигістамінну активність |
| GB8827391D0 (en) * | 1988-11-23 | 1988-12-29 | Ucb Sa | Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride |
| GB8827390D0 (en) * | 1988-11-23 | 1988-12-29 | Ucb Sa | Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride |
| US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
| TW401300B (en) * | 1992-12-25 | 2000-08-11 | Senju Pharma Co | Antiallergic composition for ophthalmic or nasal use |
| US5625358A (en) * | 1993-09-13 | 1997-04-29 | Analog Devices, Inc. | Digital phase-locked loop utilizing a high order sigma-delta modulator |
| BE1010095A3 (fr) * | 1996-04-10 | 1997-12-02 | Ucb Sa | Procede de preparation de l'acide 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl] ethoxy]-acetique et de ses sels. |
| BE1010094A3 (fr) * | 1996-04-10 | 1997-12-02 | Ucb Sa | Nouveaux [2-(1-piperazinyl)ethoxy] methyle substitues. |
-
1997
- 1997-11-26 EP EP97870193A patent/EP0919550A1/en not_active Withdrawn
-
1998
- 1998-11-17 MY MYPI98005218A patent/MY119653A/en unknown
- 1998-11-23 PE PE1998001137A patent/PE134899A1/es not_active Application Discontinuation
- 1998-11-24 CO CO98069203A patent/CO4980892A1/es unknown
- 1998-11-25 MA MA25361A patent/MA26569A1/fr unknown
- 1998-11-25 EG EG147698A patent/EG23776A/xx active
- 1998-11-25 ZA ZA9810780A patent/ZA9810780B/xx unknown
- 1998-11-25 AR ARP980105975A patent/AR017676A1/es not_active Application Discontinuation
- 1998-11-25 GC GCP199836 patent/GC0000094A/xx active
- 1998-11-25 TN TNTNSN98214A patent/TNSN98214A1/fr unknown
- 1998-11-26 WO PCT/BE1998/000184 patent/WO1999028310A1/en active IP Right Grant
- 1998-11-26 CZ CZ20001787A patent/CZ295972B6/cs not_active IP Right Cessation
- 1998-11-26 BR BR9815405-2A patent/BR9815405A/pt not_active Application Discontinuation
- 1998-11-26 DK DK98956725T patent/DK1034171T3/da active
- 1998-11-26 ES ES98956725T patent/ES2161552T3/es not_active Expired - Lifetime
- 1998-11-26 IL IL13554498A patent/IL135544A/en not_active IP Right Cessation
- 1998-11-26 CN CNB988114909A patent/CN100406448C/zh not_active Expired - Fee Related
- 1998-11-26 ID IDW20000985A patent/ID24964A/id unknown
- 1998-11-26 AU AU13277/99A patent/AU735819B2/en not_active Ceased
- 1998-11-26 KR KR1020007005660A patent/KR100557711B1/ko not_active IP Right Cessation
- 1998-11-26 UA UA2000063689A patent/UA54568C2/uk unknown
- 1998-11-26 SI SI9820072A patent/SI20325A/sl not_active IP Right Cessation
- 1998-11-26 US US09/555,021 patent/US6262057B1/en not_active Expired - Fee Related
- 1998-11-26 EP EP98956725A patent/EP1034171B1/en not_active Expired - Lifetime
- 1998-11-26 SK SK594-2000A patent/SK283237B6/sk unknown
- 1998-11-26 PL PL340724A patent/PL190871B1/pl not_active IP Right Cessation
- 1998-11-26 HU HU0100343A patent/HUP0100343A3/hu unknown
- 1998-11-26 TR TR2000/01505T patent/TR200001505T2/xx unknown
- 1998-11-26 DE DE69801163T patent/DE69801163T2/de not_active Expired - Fee Related
- 1998-11-26 RS YUP-316/00A patent/RS49904B/sr unknown
- 1998-11-26 PT PT80901733T patent/PT1034171E/pt unknown
- 1998-11-26 NZ NZ504461A patent/NZ504461A/en unknown
- 1998-11-26 JP JP2000523202A patent/JP3996348B2/ja not_active Expired - Fee Related
- 1998-11-26 RU RU2000116106/04A patent/RU2182575C2/ru not_active IP Right Cessation
- 1998-11-26 CA CA002310318A patent/CA2310318C/en not_active Expired - Fee Related
- 1998-11-26 AT AT98956725T patent/ATE203237T1/de not_active IP Right Cessation
-
1999
- 1999-01-19 TW TW088100770A patent/TWI225053B/zh not_active IP Right Cessation
-
2000
- 2000-05-11 BG BG104424A patent/BG64155B1/bg unknown
- 2000-05-23 NO NO20002631A patent/NO314692B1/no unknown
-
2001
- 2001-03-08 US US09/800,665 patent/US6335331B2/en not_active Expired - Fee Related
- 2001-09-26 GR GR20010401559T patent/GR3036702T3/el not_active IP Right Cessation
-
2007
- 2007-04-18 JP JP2007109494A patent/JP2007224042A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100791872B1 (ko) | 신규 서트랄린 염산염 다형, 그것의 제조 방법, 그것을 함유하는 조성물, 및 그것을 사용하는 방법 | |
| NO171453B (no) | Fremgangsmaate for fremstilling av krystallinsk paroxetin-hydroklorid-hemihydrat | |
| NO341013B1 (no) | Fremgangsmåte for fremstilling av atazanavirbisulfat,og former derav | |
| US9856270B2 (en) | Dolutegravir salts | |
| US20050272775A1 (en) | Polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-y1] methyl piperidine hydrochloride (Donepezil hydrochloride) and a process for producing thereof | |
| US20220356319A1 (en) | Sulcardine salts | |
| EP2155706A2 (en) | Repaglinide substantially free of dimer impurity | |
| JP2007224042A (ja) | ２−〔２−〔４−〔ビス（４−フルオロフェニル）メチル〕−１−ピペラジニル〕エトキシ〕酢酸ジヒドロクロリドの偽多形 | |
| RU2543721C2 (ru) | Цитратная соль 9е-15-(2-пирролидин-1-ил-этокси)-7,12,25-триокса-19,21,24-триазатетрацикло[18.3.1.1(2,5).1(14,18)]гексакоза-1(24),2,4,9,14,16,18(26),20,22-нонаена | |
| US20050288330A1 (en) | Process for producing a polymorphic form of (1-Benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride) | |
| US20070123565A1 (en) | Donepezil Hydrochloride Form VI | |
| US6992211B2 (en) | Crystalline form of phenylethanolamine, the preparation thereof and pharmaceutical compositions comprising the same | |
| MXPA00004826A (en) | Pseudopolymorphic forms of 2-[2-[4-[bis (4-fluorophenyl) methyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride |